Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Working Capital Changes (2017 - 2025)

VYNE Therapeutics' Other Working Capital Changes history spans 9 years, with the latest figure at -$1.1 million for Q2 2025.

  • For Q2 2025, Other Working Capital Changes fell 125.83% year-over-year to -$1.1 million; the TTM value through Jun 2025 reached -$3.5 million, down 172.61%, while the annual FY2025 figure was -$4.2 million, 568.74% down from the prior year.
  • Other Working Capital Changes reached -$1.1 million in Q2 2025 per VYNE's latest filing, down from $768000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $4.2 million in Q2 2024 to a low of -$9.5 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$774333.3, with a median of -$232000.0 recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: tumbled 17300.0% in 2022, then soared 2358.82% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.2 million in 2021, then plummeted by 685.16% to -$9.5 million in 2022, then skyrocketed by 102.26% to $214000.0 in 2023, then skyrocketed by 362.62% to $990000.0 in 2024, then tumbled by 208.48% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Other Working Capital Changes are -$1.1 million (Q2 2025), $768000.0 (Q1 2025), and $990000.0 (Q4 2024).